Patents Assigned to BioPharmX, Inc
  • Patent number: 10881672
    Abstract: Provided herein is a topical composition and related methods for making and using the composition. In a first aspect, the topical composition comprises minocycline, a magnesium salt, and a sulfite compound in a non-aqueous solvent. In yet another aspect, the topical composition comprises a tetracycline-class drug, a source of magnesium, a monohydric aliphatic alcohol, and a polyol, wherein (i) the ratio between the monohydric aliphatic alcohol and the propylene glycol is in the range of 1:1 to 99:1 by weight and (ii) the tetracycline-class drug is dissolved in the topical composition.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: January 5, 2021
    Assignee: BioPharmX, Inc.
    Inventors: Xin Chen, Maiko C. Hermsmeier, Diana Lac, Douglas W. Thomas, Noymi Yam, Akira Yamamoto
  • Patent number: 10391108
    Abstract: Provided herein is a topical composition and related methods for making and using the composition. In a first aspect, the topical composition comprises minocycline, a magnesium salt, and a sulfite compound in a non-aqueous solvent. In yet another aspect, the topical composition comprises a tetracycline-class drug, a source of magnesium, a monohydric aliphatic alcohol, and a polyol, wherein (i) the ratio between the monohydric aliphatic alcohol and the propylene glycol is in the range of 1:1 to 99:1 by weight and (ii) the tetracycline-class drug is dissolved in the topical composition.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: August 27, 2019
    Assignee: BioPharmX, Inc.
    Inventors: Xin Chen, Maiko C. Hermsmeier, Diana Lac, Douglas W. Thomas, Noymi Yam, Akira Yamamoto
  • Patent number: 10391121
    Abstract: Provided herein is a topical composition and related methods for making and using the composition. In a first aspect, the topical composition comprises a magnesium salt (e.g. magnesium chloride) dissolved in an anhydrous or non-aqueous solvent. Exemplary solvents comprise a monohydric aliphatic alcohol, and a polyol.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: August 27, 2019
    Assignee: BioPharmX, Inc.
    Inventor: Kin F. Chan
  • Patent number: 10159686
    Abstract: The present application provides a dosage form and related methods for making the dosage form. The dosage form generally comprises a hydrophilic active ingredient, a plurality of solid, porous microcarriers, each having a hydrophobic surface, an optional hydrophobic encapsulant, and a hydrophilic delivery agent, wherein (i) the hydrophilic active ingredient is associated with the plurality of solid, porous microcarriers, (ii) the plurality of solid, porous microcarriers is encapsulated by the hydrophobic encapsulant, and (iii) the hydrophilic delivery agent is physically separated from a majority of the hydrophilic active ingredient by a boundary between the hydrophilic delivery agent and the hydrophobic encapsulant. In some embodiments, the dosage form is for topical application. In some additional embodiments, the plurality of solid, porous microcarriers is formed by modifying the microcarriers to increase their hydrophobicity.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: December 25, 2018
    Assignee: BioPharmX, Inc.
    Inventor: Akira Yamamoto
  • Patent number: 10034899
    Abstract: The invention is a solid oral dosage form that is designed to deliver a supraphysiological dose of molecular iodine of 3 to 60 mg per day. The solid oral dosage form is designed to have a low risk of thyroid related adverse clinical events for patients with deficiencies of certain minerals. The solid oral dosage form includes a source of iodine, a reactive agent, and calcium or iron. The solid oral dosage form may include one or more of selenium, vitamin A, vitamin D, zinc, gamma-linolenic acid, vitamin B1, and magnesium. The solid dosage form may further comprise an enteric coating that coats ingredients that are absorbed predominantly from the intestines, such as vitamin A and D, and does not coat the source of iodine and the reactive agent.
    Type: Grant
    Filed: November 22, 2014
    Date of Patent: July 31, 2018
    Assignee: BioPharmX, Inc.
    Inventors: Jack Kessler, Robert Kehl Sink
  • Patent number: 9918998
    Abstract: Provided herein is a topical composition and related methods for making and using the composition. In a first aspect, the topical composition comprises minocycline, a magnesium salt, and a sulfite compound in a non-aqueous solvent. In yet another aspect, the topical composition comprises a tetracycline-class drug, a source of magnesium, a monohydric aliphatic alcohol, and a polyol, wherein (i) the ratio between the monohydric aliphatic alcohol and the propylene glycol is in the range of 1:1 to 99:1 by weight and (ii) the tetracycline-class drug is dissolved in the topical composition.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: March 20, 2018
    Assignee: BioPharmX, Inc.
    Inventors: Xin Chen, Maiko C. Hermsmeier, Diana Lac, Douglas W. Thomas, Noymi Yam, Akira Yamamoto
  • Patent number: 9901586
    Abstract: The present application provides a dosage form and related methods for making the dosage form. The dosage form generally comprises a hydrophilic active ingredient, a plurality of solid, porous microcarriers, each having a hydrophobic surface, an optional hydrophobic encapsulant, and a hydrophilic delivery agent, wherein (i) the hydrophilic active ingredient is associated with the plurality of solid, porous microcarriers, (ii) the plurality of solid, porous microcarriers is encapsulated by the hydrophobic encapsulant, and (iii) the hydrophilic delivery agent is physically separated from a majority of the hydrophilic active ingredient by a boundary between the hydrophilic delivery agent and the hydrophobic encapsulant. In some embodiments, the dosage form is for topical application. In some additional embodiments, the plurality of solid, porous microcarriers is formed by modifying the microcarriers to increase their hydrophobicity.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: February 27, 2018
    Assignee: BioPharmX, Inc.
    Inventor: Akira Yamamoto
  • Patent number: 9642867
    Abstract: The present application provides a dosage form and related methods for making the dosage form. The dosage form generally comprises a hydrophilic active ingredient, a plurality of solid, porous microcarriers, each having a hydrophobic surface, an optional hydrophobic encapsulant, and a hydrophilic delivery agent, wherein (i) the hydrophilic active ingredient is associated with the plurality of solid, porous microcarriers, (ii) the plurality of solid, porous microcarriers is encapsulated by the hydrophobic encapsulant, and (iii) the hydrophilic delivery agent is physically separated from a majority of the hydrophilic active ingredient by a boundary between the hydrophilic delivery agent and the hydrophobic encapsulant. In some embodiments, the dosage form is for topical application. In some additional embodiments, the plurality of solid, porous microcarriers is formed by modifying the microcarriers to increase their hydrophobicity.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: May 9, 2017
    Assignee: BioPharmX, Inc.
    Inventor: Akira Yamamoto
  • Patent number: 9474720
    Abstract: The present application provides a dosage form and related methods for making the dosage form. The dosage form generally comprises a hydrophilic active ingredient, a plurality of solid, porous microcarriers, each having a hydrophobic surface, an optional hydrophobic encapsulant, and a hydrophilic delivery agent, wherein (i) the hydrophilic active ingredient is associated with the plurality of solid, porous microcarriers, (ii) the plurality of solid, porous microcarriers is encapsulated by the hydrophobic encapsulant, and (iii) the hydrophilic delivery agent is physically separated from a majority of the hydrophilic active ingredient by a boundary between the hydrophilic delivery agent and the hydrophobic encapsulant. In some embodiments, the dosage form is for topical application. In some additional embodiments, the plurality of solid, porous microcarriers is formed by modifying the microcarriers to increase their hydrophobicity.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: October 25, 2016
    Assignee: BioPharmX, Inc.
    Inventor: Akira Yamamoto
  • Publication number: 20160287615
    Abstract: A topical composition for treatment of a skin condition comprising a fluorescent, photosensitive, or oxygen sensitive active ingredient encapsulated in a plurality of tubular microparticles for pharmaceutical use in humans is described. Some embodiments comprise a topical composition for treatment of acne that comprises an encapsulation of a tetracycline class drug, such as crystalline minocycline, in a plurality of microparticles, wherein the microparticles comprise a divalent cation, such as Mg2+ or Zn2+. The tubular microparticles may comprise Mg2CO3. Benefits of various embodiments include the lack of visible fluorescence from a fluorescent active ingredient, reduced UV degradation of a photosensitive active ingredient, reduced UV degradation of an oxygen sensitive active ingredient, sun protection factor for the skin, and sustained delivery of a therapeutic dose.
    Type: Application
    Filed: April 4, 2016
    Publication date: October 6, 2016
    Applicant: BioPharmX, Inc.
    Inventors: Kin F. Chan, Anja B. Krammer, Douglas W. Thomas
  • Publication number: 20150209296
    Abstract: The present application provides a dosage form and related methods for making the dosage form. The dosage form generally comprises a hydrophilic active ingredient, a plurality of solid, porous microcarriers, each having a hydrophobic surface, an optional hydrophobic encapsulant, and a hydrophilic delivery agent, wherein (i) the hydrophilic active ingredient is associated with the plurality of solid, porous microcarriers, (ii) the plurality of solid, porous microcarriers is encapsulated by the hydrophobic encapsulant, and (iii) the hydrophilic delivery agent is physically separated from a majority of the hydrophilic active ingredient by a boundary between the hydrophilic delivery agent and the hydrophobic encapsulant. In some embodiments, the dosage form is for topical application. In some additional embodiments, the plurality of solid, porous microcarriers is formed by modifying the microcarriers to increase their hydrophobicity.
    Type: Application
    Filed: April 3, 2015
    Publication date: July 30, 2015
    Applicant: BioPharmX, Inc.
    Inventor: Akira Yamamoto
  • Publication number: 20150147400
    Abstract: The invention is a solid oral dosage form that is designed to deliver a supraphysiological dose of molecular iodine of 3 to 60 mg per day. The solid oral dosage form is designed to have a low risk of thyroid related adverse clinical events for patients with deficiencies of certain minerals. The solid oral dosage form includes a source of iodine, a reactive agent, and calcium or iron. The solid oral dosage form may include one or more of selenium, vitamin A, vitamin D, zinc, gamma-linolenic acid, vitamin B1, and magnesium. The solid dosage form may further comprise an enteric coating that coats ingredients that are absorbed predominantly from the intestines, such as vitamin A and D, and does not coat the source of iodine and the reactive agent.
    Type: Application
    Filed: November 22, 2014
    Publication date: May 28, 2015
    Applicant: BioPharmX, Inc
    Inventors: Jack Kessler, Robert Kehl Sink